Skip to content
Search

Latest Stories

Submit Guest Post

Samir Desai to step down as Funding Circle CEO

Samir Desai to step down as Funding Circle CEO

SAMIR Desai will step down as the chief executive officer of Funding Circle, the online lender he co-founded 12 years ago.

The company said in a filing to the London Stock Exchange (LSE) on Thursday (9) that Lisa Jacobs, the managing director of the UK arm of the lending marketplace, will take over from Desai in January next year.


Desai, 38, who holds a five per cent stake in the company, will remain on its board as a non-executive director.

As the lender reported an operating profit of £35.5 million for the first half of the year, Desai said it is the “right time to step back”.

"Funding Circle is in the strongest position it has ever been after 12 years. As CEO, I have decided that now is the right time to step back from running the company and transition to a role on the board”.

“As a founder, member of the board and shareholder, I remain fully committed to Funding Circle. I'm incredibly excited about our future growth opportunities,” he said.

Following the announcement, shares of Funding Circle soared more than six per cent on LSE, trading at 149.20p. However, the stock still remains at 33 per cent of its listing price of 440p in 2018, over the concerns about its business model.

Founded as a peer-to-peer lender when the world was reeling under an economic meltdown in 2009, Funding Circle has operations in Europe and the US.

Company chair Andrew Learoyd said of Desai, “I have had the pleasure of knowing him since the early days of the business and have seen how his passion and vision have helped build Funding Circle into a highly innovative company transforming the borrowing experience for thousands of small businesses”.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less